BioSpace News Archive

Business

Selecta Biosciences and Astellas Announce Exclusive Licensing and Development Agreement for Xork IgG Protease

Selecta Biosciences, Inc. and Astellas Pharma Inc. today announced an exclusive licensing and development agreement for IdeXork (Xork).

January 9, 2023
·
10 min read
Bio NC

Precision BioSciences Recaps 2022 Accomplishments and Outlines 2023 Corporate Priorities and Planned Portfolio Milestones

Precision BioSciences today reported on its significant accomplishments in 2022 and announced its corporate priorities and anticipated clinical development and research milestones for 2023.

January 9, 2023
·
13 min read
ENA Respiratory Awarded $4.38 Million U.S. Department of Defense Agreement to Fund Development of Broad-Spectrum Antiviral INNA-051

Clinical-stage pharmaceutical company ENA Respiratory has been awarded a $4.38 million USD agreement from the U.S. Department of Defense to support ongoing research and development of INNA-051, a clinical stage first-in-class broad-spectrum antiviral innate immunomodulator, administered intranasally for the prophylaxis of respiratory viral infections and their complications.

January 9, 2023
·
3 min read
Business

AmMax Bio Enters into an Exclusive Option Agreement with Evopoint Biosciences to License a Next Generation Antibody Drug Conjugate (ADC) for the Treatment of Solid Tumors

AmMax Bio, Inc. (“AmMax”)and Evopoint Biosciences Co., Ltd (“Evopoint”) today announced that AmMax has entered into an exclusive option with Evopoint for a worldwide license, excluding Greater China, for the development and commercialization of a novel ADC for treating solid tumors.

January 9, 2023
·
3 min read
Business

Neurocrine Biosciences and Voyager Therapeutics Enter Strategic Collaboration for Development and Commercialization of Voyager’s GBA1 Program and Other Next-Generation Gene Therapies for Neurological Diseases

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) and Voyager Therapeutics, Inc. (Nasdaq: VYGR) today announced the formation of a new strategic collaboration to advance multiple gene therapies for the treatment of neurological diseases.

January 9, 2023
·
14 min read
Business

Amicus Therapeutics Reports Preliminary 2022 Revenue and Provides 2023 Strategic Outlook

Amicus Therapeutics today provided its preliminary and unaudited 2022 revenue, corporate updates, and full-year 2023 outlook.

January 9, 2023
·
15 min read
Biotech Beach

Adagene Announces Interim Data Demonstrating Safety and Confirmed Clinical Responses of Anti-CTLA-4 SAFEbody® ADG126 up to 10 mg/kg with Repeat Cycles in Combination with Anti-PD-1 Therapy from Dose Escalation Portion of Phase 1b/2 Trial

Adagene Inc. today announced data for its masked anti-CTLA-4 SAFEbody, ADG126, in combination with anti-PD-1 therapy in patients with advanced/metastatic solid tumors.

January 9, 2023
·
6 min read
Business

Ractigen Therapeutics Announces the Appointment of Harri Järveläinen as Chief Operating Officer

Ractigen Therapeutics, Inc. announced today that Dr. Harri Järveläinen has been appointed Chief Operating Officer of the Company.

January 9, 2023
·
2 min read
Business

NovalGen appoints Dr Michael Owen and Mr Scott Clark to the Board of DirectorsTwo highly experienced industry executives who bring a wealth of leadership and drug development experience

NovalGen Ltd, a biopharmaceutical company developing breakthrough cancer therapies, alongside a disruptive auto-regulation platform, announces the appointment of Dr Michael Owen and Mr Scott Clark as Non-Executive Directors to its Board, effective January 2023.

January 9, 2023
·
3 min read
Business

SoniVie Raises $60m in Round C Financing, and Appoints New Board Members

SoniVie Ltd., a medical device company developing a proprietary solution to treat hypertension, announced the completion of a $60 million series C round financing.

January 9, 2023
·
5 min read